IDEAYA announces positive Phase 2/3 data in metastatic uveal melanoma
IDEAYA Biosciences (NASDAQ:IDYA) and Servier reported breakthrough topline results today from the Phase 2/3 OptimUM-02 trial, demonstrating that the combination of darovasertib and crizotinib significantly improved outcomes for patients with first-line HLA-A*02:01-negative metastatic uveal melanoma (MUM).



_1378694_640x360_2496142915616-640x360.webp&w=3840&q=75)
_1378655_640x360_2496139331961-640x360.webp&w=3840&q=75)
_1378642_640x360_2496143427546-640x360.webp&w=3840&q=75)
_1378640_640x360_2496141379543-640x360.webp&w=3840&q=75)
_1378646_640x360_2496143427604-640x360.webp&w=3840&q=75)
_1378587_640x360_2496130115740-640x360.webp&w=3840&q=75)

_1378578_640x360_2496128579556-640x360.webp&w=3840&q=75)
_1378572_640x360_2496126019665-640x360.webp&w=3840&q=75)